Phreesia
Buying intent
41 tracked signals | Top 15 topics are below | Support and Marketing are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Phreesia's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
10d ago
13d ago
11d ago
21d ago
16d ago
17d ago
11d ago
11d ago
24d ago
19d ago
19d ago
13d ago
13d ago
13d ago
26d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Phreesia
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
See everyone, not just the first 10
18 people across every department at Phreesia, plus a LinkedIn profile link for each.
Primary products / business lines
LinkedIn company profilePhreesia was founded in 2005 to help patients take an active role in their care. Our innovative technology empowers healthcare organizations to better understand their patients and equip them with the knowledge, skills and confidence to succeed. With robust tools for registration, scheduling, payments and clinical support, Phreesia helps providers maximize efficiency and create great patient ex
Top accounts researching Phreesia
names withheld on the public pageThese are companies whose own people brought up Phreesia unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
71,482 companies · 516,730 people are researching Career Development
Phreesia's own team shows 5 signals on this topic. No one outside Phreesia has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Artificial Intelligence151,426 cos · 839,012 people
- Hiring75,708 cos · 411,263 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Engineering — 4 people; Sales — 4 people; Marketing — 2 people; HR / Talent — 1 person; Leadership — 1 person
What's been said
public posts mentioning PhreesiaUp to 9 public excerpts naming Phreesia from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.
Much of the conversation around GLP-1s focuses on their cosmetic benefits. These medications have become part of the discourse around thinness and body image. To be sure, these are important societal issues, but this focus has detracted from the real clinical benefits of GLP-1s. Rachel Bedard does an excellent job of laying this out on an episode of Search Engine. She tells PJ Vogt: “The idea that this breakthrough class of medications that had the potential to revolutionize chronic disease population health in the U.S., potentially change the expected mortality for Americans, is being funneled into this same discourse [about body image]… was really annoying to me.” Annoying, because for several years, she worked as a physician on Rikers Island, New York City’s largest prison. GLP-1s have transformed the lives of some of her most vulnerable patients. These medications have incredible benefits: they help substantially lower the risk of cardiovascular disease and help patients manage severe chronic conditions like diabetes and kidney disease. We should not let the oversized health benefits of GLP-1s get lost by focusing only on weight loss. This is why we at Phreesia Network Solutions focus on supporting patients with evidence-based resources so they can understand the full implications of starting and staying on a medication. Brands have a unique opportunity to inform patients about the life-saving clinical benefits of GLP-1s at the point of care. Leave a comment with your thoughts on what current conversations about GLP-1s are missing.
May 2026Strategic priorities
Earnings call; SEC filingsMarket Leader; Cash Flow
What changed recently
Earnings call; SEC filingsMarket Leader; Cash Flow